Ceruloplasmin replacement therapy

Aceruloplasminemia is a monogenic disease caused by mutations in the ceruloplasmin gene that result in loss of protein ferroxidase activity. Ceruloplasmin plays a role in iron homeostasis, and its activity impairment leads to iron accumulation in liver, pancreas, and brain. Iron deposition promotes diabetes, retinal degeneration, and progressive neurodegeneration.

    Related Conference of Ceruloplasmin replacement therapy

    November 21-22, 2018

    14th World Congress on Endocrinology & Diabetes

    Paris, France
    November 26-27, 2018

    26th International Diabetes and Healthcare Conference

    Helsinki, Finland
    November 26-27, 2018

    13th European Diabetes and Endocrinology Congress

    Dublin, Ireland
    February 27-28, 2019

    Asia Pacific Diabetes and Endocrinology Congress

    Radisson Hotel Narita, Tokyo, Japan

    April 17-18, 2019

    21st Asia Pacific Diabetes Conference

    Osaka,Japan
    May 17-18, 2019

    2nd Global Experts Meeting on Diabetes, Hypertension & Metabolic Syndrome

    Holiday Inn Singapore Atrium | Singapore
    May 30-31, 2019

    2nd Global Meeting on Diabetes and Endocrinology

    Istanbul, Turkey
    June 10-11, 2019

    28th European Diabetes Congress

    | Edinburgh, Scotland
    July 24-25, 2019

    29th World Diabetes & Heart Congress

    Melbourne, Australia
    July 29-30, 2019

    12th International Conference on Diabetes & Metabolism

    Chicago | Illinois| USA
    Oct 03-04, 2019

    Euro Diabetes Congress & Expo

    | Paris, France

    Ceruloplasmin replacement therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in